<DOC>
	<DOC>NCT00566878</DOC>
	<brief_summary>The objective is to determine if alglucosidase alfa is present in breast milk from mothers with Pompe Disease being treated with alglucosidase alfa and to measure breast milk production and composition in women with Pompe Disease who receive alglucosidase alfa.</brief_summary>
	<brief_title>Pompe Lactation Sub-Registry</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Must be enrolled in Pompe Registry (NCT00231400) Must be pregnant and intend to breastfeed or be currently lactating and receive at least one infusion of alglucosidase alfa while lactating Provide a signed Patient Information and Authorization form to participate in the subregistry prior to any subregistryrelated assessments are performed Agree to adhere to the subregistry guidelines for antibody testing and recommended schedule of assessments. Patients will be excluded from this subregistry if they have received an investigational drug (excluding alglucosidase alfa in regions where alglucosidase alfa is not commercially available) within 30 days prior to Visit 1 breast milk collection</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Glycogen Storage Disease</keyword>
	<keyword>GSD-II</keyword>
	<keyword>Pompe Disease</keyword>
	<keyword>Pompe Disease (Late-Onset)</keyword>
	<keyword>Acid Maltase Deficiency Disease</keyword>
	<keyword>Glycogenosis II</keyword>
</DOC>